A Phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf - Chalmers, J D; Gupta, A; Chotirmall, S H (ERJ Open Res, 2023)
et al.